Clinical trials

Metabolic aging, fasting and metformin

The presence of a “metabolic clock” that regulates aging involves the accumulation of metabolic alterations and a decline in metabolic homeostasis and biological fitness. An...

Cerevance raising $60m for brain disease drug discovery

Company awaits Phase 2 trial readout for new Parkinson’s drug as part of its mission to combat brain disease. In the world of Longevity start-ups,...

Proving the Longevity potential of NAD+

Talking sirtuins, NAD+ and trials with Elysium Health CEO Eric Marcotulli. When it comes to the world of consumer anti-aging supplements, there are few higher-profile...

LSD = Longevity (and) stalled dementia?

New York-based biotech company Eleusis has completed a phase 1 trial of the psychedelic drug LSD and is moving forward to phase 2. Could...

EnClear bags $10m to start first in-human

We talk exclusively with the Longevity start-up targeting neurodegenerative disease with novel therapeutic filtration (device) technology. Its mission: access and control cerebrospinal fluid to get...

Alkahest Parkinson’s clinical trial gets funding boost

Alkahest announced today that they have initiated a phase 2 clinical trial with funding from the Michael J. Fox Foundation (MJFF). Today's press release reveals...

“Human-on-a-Chip” OOC to revolutionise preclinical

New system of linked mini-organs heralds a new era of comprehensive drug testing that is faster and more efficient than anything seen before. OOC...

Singapore to start human Longevity studies

Prof Brian Kennedy: "One of the reasons I came to Singapore is that the government recognises the problem of aging." In this second part of...

Prof Brian Kennedy: Talking biomarkers and interventions

“We're not trying to make billionaires live longer, we're trying to make everybody live longer.” When it comes to thought leaders in the Longevity sector,...

Elysium announces epigenetic aging clinical trial

Elysium Health is to study correlations between epigenetic aging and amounts of NAD+ and other biomarkers in a new clinical trial. Fresh on the back...

Talking pipeline with resTORbio’s Joan Mannick

While Phase 3 trial of RTB101 for respiratory illness did not meet primary endpoint, company presses-on with Parkinson’s trial for TORC1 inhibitor: Results expected...

Alkahest’s age-related therapy enters stage 2

Age-related macular degeneration can lead to major vision loss. But researchers at Alkahest have announced they are moving forward with trials for a new...

It’s all in the numbers; small sets of numbers

AI start-up NetraMark targets $3 million seed round while identifying that an exciting repurposing candidate has potential for indication expansion into Longevity. “I won’t tell you...

Project 21 well on track

SENS Foundation business model evolves to focus on spin-outs. At the recent Longevity Forum in London, one of the keynote sessions was delivered by Dr...

Pay-to-play age reduction has $1m price tag

This is the world's first IRB-approved clinical trial aimed at reversing aging by at least 20 years; it is also the world's most expensive...

Gene editing: “fear and excitement in equal measure”

Top lawyer highlights concerns raised by expected growth in gene editing sector. Earlier this year, a major US financial analyst firm identified Longevity as one...

Dogs or mice? Our exclusive with Dr Steven Austad

If we're going to find robust solutions for aging, we may need more than mouse models — argues the University of Alabama at Birmingham's...

Biogen’s Alzheimer’s drug is back from the dead

From Biogen, the first drug to actually slow the decline of Alzheimer's disease, rather than just ameliorate the symptoms, is alive and seeking FDA...

Deep dive report: From mice to men

Mouse models used for research in aging therapies can only go so far in progressing human Longevity. Longevity.Technology: In this deep dive report we talk with experienced...

Dr Nir Barzilai: Creating a template for all aging trials

There are few voices in Longevity research as distinctive as Dr Nir Barzilai’s. Brimming with jokes and references, his sentences digress and then return to...

Latest articles

Longevity 2020: shaping-up nicely

Over 45 confirmed speakers for this 5-day online event and a big thank you for your interest. We're moving fast! Longevity 2020 started just over...

Telomeres on repeat to inhibit inflamm-aging

Coming around again – Italian team hopes to use repeated nucleobases to delay aging through extending telomeres. Inflammation is a double-edged sword; while it is necessary...

Join me at my 100th birthday party in 2049!

We speak with GRG's Johnny Adams, a key contributor to the Longevity2020 online conference, about his quest for more healthy years. One of the speakers at this month’s...

Call for consensus in defining biological aging

We speak with a key contributor to the Longevity2020 online conference about biological aging. UK start-up AgeCurve is focused on the measurement of aging and...

Sign-up for daily news on the research, investments and technologies driving the Longevity market.

Sign-up for daily news on the research, investments and technologies driving the Longevity market.